Mylan has launched in the UK the Semglee (insulin glargine) biosimilar that it developed with Biocon. Available in 100 units/ml pre-filled pens, the once-a-day long-acting basal insulin is indicated to treat diabetes mellitus in adults and children above two years of age.
Mylan has launched in the UK the Semglee (insulin glargine) biosimilar that it developed with Biocon. Available in 100 units/ml pre-filled pens, the once-a-day long-acting basal insulin is indicated to treat diabetes mellitus in adults and children above two years of age.
Jean-Yves Brault, Mylan’s country manager for the UK, said “insulin glargine biosimilars play a key role in the challenges faced...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
